UCB: promising results in psoriasis

(CercleFinance.com) - UCB shares were up slightly in a flat BEL 20 index index on Monday morning, after the group announced further positive results were for an experimental treatment for psoriasis.


UCB announced on Friday evening that two-year data on bimekizumab, its monoclonal antibody for moderate-to-severe psoriasis, showed that the product continued to be effective in maintenance therapy.

It said that a majority of patients who achieved complete or near-complete clearance of their lesions after 16 weeks of treatment continued to remain fully in shape thereafter, regardless of whether the product was administered every four or eight weeks.


Copyright (c) 2021 CercleFinance.com. All rights reserved.